Politics · India Bureau
Supreme Court condemns 'carnage' of cancer drug price markups in India
India's apex court has questioned steep markups on cancer medications and called for regulatory intervention to make life-saving drugs more affordable. Petitioners have urged the court to regulate pricing of pharmaceuticals, medical equipment, and generic medicines across the nation.
LSN India ·
The Supreme Court of India has expressed serious concern over the significant price disparities in cancer drugs, describing the situation as 'carnage' during proceedings on a public interest petition seeking judicial intervention in pharmaceutical pricing.
Petitioners have approached the apex court with demands to regulate the prices of essential cancer medications, medical devices, and generic drugs to improve accessibility for patients across the country. The case highlights growing concerns about affordability of life-saving treatments and the financial burden placed on patients and families seeking cancer care.
The court's strong language underscores mounting judicial scrutiny of pharmaceutical pricing practices in India, where markup variations between different regions and retailers have created significant disparities in drug costs. Industry observers note that price regulation mechanisms have faced challenges in addressing the gap between manufacturer costs and retail prices for critical medications.
The petition seeks comprehensive regulatory oversight to standardize pricing structures and prevent excessive markups that render essential medicines inaccessible to large sections of the population. The court's intervention signals potential pressure on the government and pharmaceutical regulators to review existing price control frameworks and implement stricter measures to curb unreasonable pricing practices.